| scholarly article | Q13442814 |
| P356 | DOI | 10.1310/0GU7-6X27-MMHE-5ALE |
| P698 | PubMed publication ID | 15472793 |
| P50 | author | Matthew Law | Q89298565 |
| Mark S Clements | Q100391680 | ||
| P2093 | author name string | Andrew Carr | |
| Jennifer Hoy | |||
| Simon Mallal | |||
| David A Cooper | |||
| Allison Martin | |||
| John Chuah | |||
| Don Smith | |||
| PIILR Study Group | |||
| P2860 | cites work | Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea | Q28373171 |
| An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score | Q39219932 | ||
| Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial | Q41710792 | ||
| Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study | Q42625324 | ||
| A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors | Q43613003 | ||
| Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. | Q43682173 | ||
| Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection. | Q43935760 | ||
| Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. | Q44024987 | ||
| Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study | Q44156639 | ||
| Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study | Q44235934 | ||
| An objective case definition of lipodystrophy in HIV-infected adults: a case-control study | Q44350196 | ||
| Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy | Q44406903 | ||
| Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study | Q44820677 | ||
| Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance | Q47886909 | ||
| A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. | Q51560679 | ||
| Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. | Q51563048 | ||
| "Buffalo hump" in men with HIV-1 infection. | Q51571024 | ||
| A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study | Q58065019 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 192-200 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | HIV Clinical Trials | Q15756361 |
| P1476 | title | Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study). | |
| P478 | volume | 5 |
| Q47272996 | Changes in facial fat in HIV-related lipoatrophy, wasting, and weight gain measured by magnetic resonance imaging |
| Q46794117 | Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients |
| Q46407316 | Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone |
Search more.